Home
Line Bjørge's picture

Line Bjørge

Professor
  • E-mailLine.Bjorge@uib.no
  • Visitor Address
    Haukeland universitetssykehus, Laboratoriebygget
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Phenotypic Characterization by Mass Cytometry of the Microenvironment in Ovarian Cancer and Impact of Tumor Dissociation Methods. Cancers. 1-18.
  • Show author(s) 2021. Decidual and placental NOD1 is associated with inflammation in normal and preeclamptic pregnancies . Placenta. 23-31.
  • Show author(s) 2020. Near-Infrared Fluorescent Imaging for Monitoring of Treatment Response in Endometrial Carcinoma Patient-Derived Xenograft Models. Cancers. 1-18.
  • Show author(s) 2020. High degree of heterogeneity of PD-L1 and PD-1 from primary to metastatic endometrial cancer. Gynecologic Oncology. 260-267.
  • Show author(s) 2020. Establishment of a novel cancer cell line derived from vulvar carcinoma associated with lichen sclerosus exhibiting a fibroblast-dependent tumorigenic potential. Experimental Cell Research. 1-9.
  • Show author(s) 2020. DNA methylation signatures to predict the cervicovaginal microbiome status. Clinical Epigenetics.
  • Show author(s) 2020. Cholesterol crystals and NLRP3 mediated inflammation in the uterine wall decidua in normal and preeclamptic pregnancies. Frontiers in Immunology. 1-12.
  • Show author(s) 2020. CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model . EBioMedicine. 1-12.
  • Show author(s) 2020. CD24-targeted fluorescence imaging in patient-derived xenograft models of high-grade serous ovarian carcinoma. EBioMedicine. 1-13.
  • Show author(s) 2019. Shared heritability and functional enrichment across six solid cancers. Nature Communications. 1-23.
  • Show author(s) 2019. Niraparib plus bevacizumab versus niraparib alone for platinum-sensitive recurrent ovarian cancer (NSGO-AVANOVA2/ENGOT-ov24): a randomised, phase 2, superiority trial. The Lancet Oncology. 1409-1419.
  • Show author(s) 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 (FMS-like tyrosine kinase receptor 1) biomarker specificity. Hypertension. 1136-1143.
  • Show author(s) 2019. Influence of p53 isoform expression on survival in high-grade serous ovarian cancers. Scientific Reports. 1-11.
  • Show author(s) 2019. Genetic data from nearly 63,000 women of European descent predicts DNA methylation biomarkers and epithelial ovarian cancer risk. Cancer Research. 505-517.
  • Show author(s) 2019. Final results from GCIG/ENGOT/AGO-OVAR 12, a randomised placebo-controlled phase III trial of nintedanib combined with chemotherapy for newly diagnosed advanced ovarian cancer. International Journal of Cancer. 1-10.
  • Show author(s) 2019. Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American women. Cancer Medicine. 2503-2513.
  • Show author(s) 2019. Concentration of fibrin monomer in pregnancy and during the postpartum period. Annals of Clinical Biochemistry. 1-9.
  • Show author(s) 2019. Association between the cervicovaginal microbiome, BRCA1 mutation status, and risk of ovarian cancer: a case-control study. The Lancet Oncology. 1171-1182.
  • Show author(s) 2019. A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24. Cancer Chemotherapy and Pharmacology. 791-798.
  • Show author(s) 2018. rs495139 in the TYMS-ENOSF1 region and risk of ovarian carcinoma of mucinous histology. International Journal of Molecular Sciences. 1-13.
  • Show author(s) 2018. Within-subject biological variation of activated partial thromboplastin time, prothrombin time, fibrinogen, factor VIII and von Willebrand factor in pregnant women. Clinical Chemistry and Laboratory Medicine. 1-12.
  • Show author(s) 2018. White blood cell BRCA1 promoter methylation status and ovarian cancer risk. Annals of Internal Medicine. 326-334.
  • Show author(s) 2018. Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLOS ONE. 1-13.
  • Show author(s) 2018. Preoperative tumor texture analysis on MRI predicts high-risk disease and reduced survival in endometrial cancer. Journal of Magnetic Resonance Imaging. 1637-1647.
  • Show author(s) 2018. Preoperative quantitative dynamic contrast-enhanced MRI and diffusion-weighted imaging predict aggressive disease in endometrial cancer. Acta Radiologica. 1010-1017.
  • Show author(s) 2018. Placental inflammation in pre-eclampsia by Nod-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Clinical and Experimental Immunology. 84-94.
  • Show author(s) 2018. Placental inflammation by HMGB1 activation of TLR4 at the syncytium. Placenta. 53-61.
  • Show author(s) 2018. High expression of the p53 isoform ? is associated with reduced progression-free survival in uterine serous carcinoma. BMC Cancer. 1-10.
  • Show author(s) 2018. Asparaginase-like protein 1 expression in curettage independently predicts lymph node metastasis in endometrial carcinoma: a multicentre study. BJOG: An International Journal of Obstetrics and Gynaecology. 1695-1703.
  • Show author(s) 2018. Adult height is associated with increased risk of ovarian cancer: A Mendelian randomisation study. British Journal of Cancer. 1123-1129.
  • Show author(s) 2018. A transcriptome-wide association study among 97,898 women to identify candidate susceptibility genes for epithelial ovarian cancer risk. Cancer Research. 5419-5430.
  • Show author(s) 2017. Proteomic profiling of endometrioid endometrial cancer reveals differential expression of hormone receptors and MAPK signaling proteins in obese versus non-obese patients. OncoTarget. 106989-107001.
  • Show author(s) 2017. Preoperative imaging markers and PDZ-binding kinase tissue expression predict low-risk disease in endometrial hyperplasias and low grade cancers. OncoTarget. 68530-68541.
  • Show author(s) 2017. Late-week surgical treatment of endometrial cancer is associated with worse long-term outcome: Results from a prospective, multicenter study. PLOS ONE. 1-12.
  • Show author(s) 2017. In vivo MR spectroscopy predicts high tumor grade in endometrial cancer. Acta Radiologica. 497-505.
  • Show author(s) 2017. Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics. 680-691.
  • Show author(s) 2017. Expression of L1CAM in curettage or high L1CAM level in preoperative blood samples predicts lymph node metastases and poor outcome in endometrial cancer patients. British Journal of Cancer. 840-847.
  • Show author(s) 2017. C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease. PLOS ONE. 1-12.
  • Show author(s) 2017. Analyses of germline variants associated with ovarian cancer survival identify functional candidates at the 1q22 and 19p12 outcome loci. OncoTarget. 64670-64684.
  • Show author(s) 2017. A national, prospective observational study of first recurrence after primary treatment for gynecological cancer in Norway. Acta Obstetricia et Gynecologica Scandinavica. 1162-1169.
  • Show author(s) 2016. Tissue and imaging biomarkers for hypoxia predict poor outcome in endometrial cancer. OncoTarget. 69844-69856.
  • Show author(s) 2016. The genomic landscape and evolution of endometrial carcinoma progression and abdominopelvic metastasis. Nature Genetics. 848-855.
  • Show author(s) 2016. The antihypertensive MTHFR gene polymorphism rs17367504-G is a possible novel protective locus for preeclampsia. Journal of Hypertension. 132-139.
  • Show author(s) 2016. The HDACi panobinostat shows growth inhibition both in vitro and in a bioluminescent orthotopic surgical xenograft model of ovarian cancer. PLOS ONE.
  • Show author(s) 2016. Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Oncology. 78-89.
  • Show author(s) 2016. PALB2, CHEK2 and ATM rare variants and cancer risk: Data from COGS. Journal of Medical Genetics. 800-811.
  • Show author(s) 2016. Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: Results from a large-scale collaboration. OncoTarget. 72381-72394.
  • Show author(s) 2016. Implementing medical abortion with mifepristone and misoprostol in Norway 1998-2013. International Journal of Epidemiology.
  • Show author(s) 2016. Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. Nature Communications.
  • Show author(s) 2016. Changes in Chromatin Structure in Curettage Specimens Identifies High-Risk Patients in Endometrial Cancer. Cancer Epidemiology, Biomarkers and Prevention. 61-67.
  • Show author(s) 2016. BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute. 1-10.
  • Show author(s) 2016. Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. OncoTarget. 69097-69110.
  • Show author(s) 2016. Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics. 741-756.
  • Show author(s) 2016. Adverse pregnancy outcomes after treatment for cervical intraepithelial neoplasia. Obstetrics and Gynecology. 1265-1273.
  • Show author(s) 2016. Adult body-mass index and ovarian cancer risk by subtype: A Mendelian randomization study. International Journal of Epidemiology. 884-895.
  • Show author(s) 2015. Tumour apparent diffusion coefficient is associated with depth of myometrial invasion and is negatively correlated to tumour volume in endometrial carcinomas. Clinical Radiology. 487-494.
  • Show author(s) 2015. The Norwegian preeclampsia family cohort study: a new resource for investigating genetic aspects and heritability of preeclampsia and related phenotypes. BMC Pregnancy and Childbirth. 1-12.
  • Show author(s) 2015. Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics. 5955-5964.
  • Show author(s) 2015. Refined phenotyping identifies links between preeclampsia and related diseases in a Norwegian preeclampsia family cohort. Journal of Hypertension. 2294-2302.
  • Show author(s) 2015. Preoperative tumor size at MRI predicts deep myometrial invasion, lymph node metastases, and patient outcome in endometrial carcinomas. International Journal of Gynecological Cancer. 459-466.
  • Show author(s) 2015. Network-based integration of GWAS and gene expression identifies a HOX-centric network associated with serous ovarian cancer risk. Cancer Epidemiology, Biomarkers and Prevention. 1574-1584.
  • Show author(s) 2015. Metabolic tumor volume on 18F-FDG PET/CT improves preoperative identification of high-risk endometrial carcinoma patients. Journal of Nuclear Medicine. 1191-1198.
  • Show author(s) 2015. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics. Placenta. 1455-1462.
  • Show author(s) 2015. Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics. 164-171.
  • Show author(s) 2015. Genome-wide significant risk associations for mucinous ovarian carcinoma. Nature Genetics. 888-897.
  • Show author(s) 2015. Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology. 542-548.
  • Show author(s) 2015. Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology. 689-697.
  • Show author(s) 2015. Common genetic variation in cellular transport genes and epithelial ovarian cancer (EOC) risk. PLOS ONE.
  • Show author(s) 2015. Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications.
  • Show author(s) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Show author(s) 2015. Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients. Cancer Immunology and Immunotherapy. 337-347.
  • Show author(s) 2014. Medical abortion with mifepristone and home administration of misoprostol up to 63 days' gestation. Acta Obstetricia et Gynecologica Scandinavica. 647-653.
  • Show author(s) 2014. Landscape of genomic alterations in cervical carcinomas. Nature. 371-375.
  • Show author(s) 2014. Increased microvascular proliferation is negatively correlated to tumour blood flow and is associated with unfavourable outcome in endometrial carcinomas. British Journal of Cancer. 107-114.
  • Show author(s) 2014. Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics. 481-497.
  • Show author(s) 2014. First in-mouse development and application of a surgically relevant xenograft model of ovarian carcinoma. PLOS ONE.
  • Show author(s) 2014. Consortium analysis of diet-gene interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition & Food Research. 2023-2035.
  • Show author(s) 2013. Validity of the diagnosis of pre-eclampsia in the Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 943-950.
  • Show author(s) 2013. Validity of pre-eclampsia diagnosis in Medical Birth Registry of Norway. Acta Obstetricia et Gynecologica Scandinavica. 243-950.
  • Show author(s) 2013. Menstrual Cycle and Respiratory Symptoms in a General Nordic-Baltic Population. American Journal of Respiratory and Critical Care Medicine. 366-373.
  • Show author(s) 2013. Dynamic contrast-enhanced MRI in endometrial carcinoma identifies patients at increased risk of recurrence. European Radiology. 2916-2925.
  • Show author(s) 2012. Pregnancy outcomes after paternal radiofrequency field exposure aboard fast patrol boats. Journal of Occupational and Environmental Medicine. 431-438.
  • Show author(s) 2012. No effects of MRI scan on male reproduction hormones. Reproductive Toxicology. 133-139.
  • Show author(s) 2012. Er det mulig å få pålitelig kunnskap om psykiske senvirkninger etter provosert abort? Tidsskrift for Den norske legeforening. 1450-1452.
  • Show author(s) 2011. Increased endoplasmic reticulum stress in decidual tissue from pregnancies complicated by fetal growth restriction with and without pre-eclampsia. Placenta. 823-829.
  • Show author(s) 2011. Identification of ACOX2 as a shared genetic risk factor for preeclampsia and cardiovascular disease. European Journal of Human Genetics. 796-800.
  • Show author(s) 2011. A transcriptional profile of the decidua in preeclampsia. American Journal of Obstetrics and Gynecology. 84, e1-84, e27.
  • Show author(s) 2010. STOX2 but not STOX1 is differently expressed in preeclampstic decidua from Norwegian women: data from the Second Nord-Trondelag Health Study. Molecular human reproduction. 960-968.
  • Show author(s) 2010. Medical Abortion at 63 to 90 Days of Gestation. Obstetrics and Gynecology. 962-968.
  • Show author(s) 2010. Matrix Metalloproteinase 1 in Pre-eclampsia and Fetal Growth Restriction: Reduced Gene Expression in Decidual Tissue and Protein Expression in Extravillous Trophoblasts. Placenta. 615-620.
  • Show author(s) 2009. Oral contraception, body mass index, and asthma: A cross-sectional Nordic-Baltic population survey. Journal of Allergy and Clinical Immunology. 391-397.
  • Show author(s) 2008. Whole-genome microarray and targeted placental analysis of angiogenesis-regulating gene expression (ENG, FLT1, VEGF, PIGF) from pre-eclamptic and small-for-gegstational-age pregnancies. Journal of Maternal-Fetal & Neonatal Medicine. 158-165.
  • Show author(s) 2006. Placental expression of glycophosphatidylinositol (GPI)-anchored proteins in paroxysmal nocturnal haemoglobinuria. Scandinavian Journal of Immunology.
  • Show author(s) 2006. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scandinavian Journal of Immunology. 355-364.
  • Show author(s) 2006. Minimal residual disease in ovarian cancer as a target for complement-mediated mAb immunotherapy. Scandinavian Journal of Immunology. 355-364.
  • Show author(s) 2006. Cardiopulmonary distress during obstetrical anaesthesia: attempts to diagnose amniotic fluid embolism in a case series of suspected allergic anaphylaxis. Acta Anaesthesiologica Scandinavica. 324-330.
  • Show author(s) 2005. Ascitic complement system in ovarian cancer. British Journal of Cancer. 895-905.
Lecture
  • Show author(s) 2019. The NLRP3 inflammasome expression by maternal and fetal cells in the uterine wall and association with preeclampsia development. .
  • Show author(s) 2019. NLRP3 inflammasome expression by maternal and fetal cells in decidua and its association with preeclampsia .
  • Show author(s) 2019. Divergent regulation of decidual oxidative stress response in preeclampsia with and without fetal growth restriction.
  • Show author(s) 2017. Inflammation in preeclampsia by NOD-like receptor protein (NLRP)3 inflammasome activation in trophoblasts.
  • Show author(s) 2017. An inflammatory role for NOD1 in decidua and placenta of normal and preeclamptic pregnancies.
  • Show author(s) 2014. Inflammation in normal and preeclamptic pregnancies.
Academic lecture
  • Show author(s) 2021. The link between inflammatory and vascular pathology and sFlt-1 expression at the maternal-fetal interface in preeclampsia.
  • Show author(s) 2021. Systemic immunological perturbations and placental pathology in preeclampsia.
  • Show author(s) 2018. Decidual inflammation in normal and preeclamptic pregnancies.
  • Show author(s) 2016. Decidual Nrf2-mediated oxidative stress response in preeclampsia and fetal growth restriction.
  • Show author(s) 2015. The inflammatory role of HMGB1 in preeclampsia.
  • Show author(s) 2013. Preeclampsia and cardiovascular disease - shared causative genetic mechanisms?
  • Show author(s) 2013. Arvelighet av kardiovaskulær sykdom i en familiekohort med økt forekomst av preeklampsi.
  • Show author(s) 2013. A preeclampsia genome-wide linkage scan in Norwegian families.
  • Show author(s) 2011. MEDICAL ABORTION WITH HOME ADMINISTRATION OF MISOPROSTOL UP TO 63 DAYS GESTATION.
  • Show author(s) 2010. Norway: In transition from surgical to medical termination.
  • Show author(s) 2010. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia.
  • Show author(s) 2008. Women's choices: Why do they opt for medical abortion?
Doctoral dissertation
  • Show author(s) 2020. Biomarkers and preclinical models for more precise diagnosis and personalized treatment of oral and vulva carcinomas - Study on human samples and experimental models.
  • Show author(s) 2019. Rethinking Gynecological High- Grade Serous Carcinoma. Portraying the p53 isoform landscape and development of a new preclinical for optical imaging in xenograft models.
  • Show author(s) 1996. Complement regulatory proteins in malignancies. -.
Academic chapter/article/Conference paper
  • Show author(s) 2007. Immunologi og reproduksjon. 6 pages.
Abstract
  • Show author(s) 2021. The link between inflammatory and vascular pathology and sFlt-1 expression at the maternal-fetal interface in preeclampsia. Placenta. e13-e14.
  • Show author(s) 2021. Systemic immunological perturbations and placental pathology in preeclampsia. Placenta. e18-e19.
  • Show author(s) 2019. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy . Clinical medicine (London).
  • Show author(s) 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia. Pregnancy Hypertension. S15.
  • Show author(s) 2019. The NLRP3 inflammasome expression by maternal and fetal cells in the uterine wall and association with preeclampsia development. Placenta. e15.
  • Show author(s) 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity. Pregnancy Hypertension. S5.
  • Show author(s) 2019. Divergent regulation of decidual oxidative stress response in preeclampsia with and without fetal growth restriction. Pregnancy Hypertension. S21.
  • Show author(s) 2018. Decidual inflammation in normal and preeclamptic pregnancies. Pregnancy Hypertension. S33-S34.
  • Show author(s) 2017. No evidence that genetic variation in the myeloid-derived suppressor cell pathway influences ovarian cancer survival. Cancer Epidemiology, Biomarkers and Prevention. 420-424.
  • Show author(s) 2017. Inflammation in preeclampsia by NOD-like receptor protein (NLRP)3 inflammasome activation in trophoblasts. Pregnancy Hypertension. 21.
  • Show author(s) 2017. An inflammatory role for TLR3 in decidua and placenta of normal and preeclamptic pregnancies. Placenta. 278.
  • Show author(s) 2017. An inflammatory role for NOD1 in decidua and placenta of normal and preeclamptic pregnancies. Placenta. 235.
  • Show author(s) 2016. NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies. Placenta. 88-88.
  • Show author(s) 2015. The inflammatory role of HMGB1 in preeclampsia. Pregnancy Hypertension. 229.
  • Show author(s) 2015. Identifying a novel link between preeclampsia and chronic hypertension in the MTHFR gene using the population based Norwegian HUNT Study. Pregnancy Hypertension. 243-244.
  • Show author(s) 2015. A genetic connection between preeclampsia and chronic hypertension in Norwegian families. Pregnancy Hypertension. 138-139.
  • Show author(s) 2013. PANOBINOSTAT / CARBOPLATIN DELAY POSTSURGICAL RELAPSE OF OVARIAN CARCINOMA IN AN ORTHOTOPIC MOUSE MODEL. International Journal of Gynecological Cancer. 1 pages.
  • Show author(s) 2013. Arvelighet av kardiovaskulær sykdom i en familiekohort med økt forekomst av preeklampsi. Gynekologen. 43-44.
  • Show author(s) 2013. A preeclampsia genome-wide linkage scan in Norwegian families. Pregnancy Hypertension. 64.
  • Show author(s) 2012. Venøs trombose i svangerskapet: Internasjonale retningslinjer blir norske. Gynekologen. 43.
  • Show author(s) 2012. Trender i bruken av medikamentell abort i Noreg. Gynekologen.
  • Show author(s) 2012. Medical abortion with home administration of misoprostol up to 63 days gestation. Acta Obstetricia et Gynecologica Scandinavica. 33-34.
  • Show author(s) 2012. Medical abortion at 9-12 weeks. Acta Obstetricia et Gynecologica Scandinavica. 49-49.
  • Show author(s) 2012. INVESTIGATING GENETIC PREDISPOSITION AND CLINICAL OCCURRENCE OF PREECLAMPSIA AND CARDIOVASCULAR DISEASE THROUGH A FAMILY-BASED DESIGN. Placenta. A82-A82.
  • Show author(s) 2012. HPV-vaksinasjon – er kunnskapsnivået hos norske medisinetstudenter og allmennleger tilstrekkelig høyt? Gynekologen. 43.
  • Show author(s) 2012. Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: Analysis of tumor growth and response to therapy. Acta Obstetricia et Gynecologica Scandinavica. 16-17.
  • Show author(s) 2012. A population and family based study design to investigate genetic predisposition to preeclampsia and cardiovascular disease. The Norwegian Preeclampsia Family Study. Acta Obstetricia et Gynecologica Scandinavica. 135-136.
  • Show author(s) 2011. Establishment of a Norwegian Preeclampsia Family Biobank. Placenta. A85-A85.
  • Show author(s) 2011. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia and fetal growth restriction. Placenta.
  • Show author(s) 2010. Endoplasmatic reticulum stress in decidual tissue from pregnancies complicated with preeclampsia. Hypertension in Pregnancy.
  • Show author(s) 2010. Classification of pre-eclamptic pregnancies in health registries. An evaluation of criteria selected and pregnancies included in the Medical Birth Registry of Norway. Hypertension in Pregnancy.
Poster
  • Show author(s) 2019. What you should know about tumor reductive surgery in advanced ovarian cancer – Clinical recommendations from a patient perspective.
  • Show author(s) 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia .
  • Show author(s) 2019. Toll-Like Receptor-3 expression by maternal and fetal cells at the maternal-fetal interface is associated with development of preeclampsia.
  • Show author(s) 2019. Metabolomics identifies placental dysfunction and confirms Flt-1 biomarker specificity.
  • Show author(s) 2019. EP889 improved cytoreduction of ovarian cancer using CD24 targeted fluorescence image guided surgery in a preclinical murine model.
  • Show author(s) 2018. TLR3 expression and activation at the maternal-fetal interface in pregnancy.
  • Show author(s) 2018. Inflammation at the uterine wall lining in pregnancy.
  • Show author(s) 2017. Engraftement optimization, charaterization and tumor spread tracking by preclinical imaging in ovarian cancer patiant.
  • Show author(s) 2017. An inflammatory role for TLR3 in decidua and placenta of normal and preeclamptic pregnancies.
  • Show author(s) 2016. Toll-like receptor 3 expression and activation at the maternal-fetal interface in pregnancy.
  • Show author(s) 2016. Nrf2-mediated oxidative stress response at the maternal-fetal interface in preeclampsia and fetal growth restriction.
  • Show author(s) 2016. NLRP3 inflammasome expression and activation at the maternal-fetal interface in preeclamptic and healthy pregnancies.
  • Show author(s) 2015. The inflammatory role of HMGB1 in preeclamptic and normal pregnancies.
  • Show author(s) 2015. The NLRP3 inflammasome in placentas from preeclamptic and healthy pregnancies.
  • Show author(s) 2015. Metabolic profiles of placenta in preeclampsia using HR-MAS MRS metabolomics.
  • Show author(s) 2014. Heritability of cardiovascular diseases in a preeclampsia family cohort.
  • Show author(s) 2014. A genetic connection between preeclampsia and chronic hypertension in Norwegian families.
  • Show author(s) 2013. Panobinostat / carboplatin delay postsurgical relapse of ovarian carcinomas in an orthotopic mouse model.
  • Show author(s) 2013. Histone deacetylase inhibisjon i kombinasjon med platinum i en klinisk relevant ortotopisk musemodel for ovarialcancer.
  • Show author(s) 2013. Heritability of cardiovascular diseases in a preeclampsia family cohort.
  • Show author(s) 2012. A family based cohort study design to investigate genetic predisposition to preeclampsia and cardiovascular disease. The Norwegian Preeclampsia Family Study.
  • Show author(s) 2011. Establishment of a Norwegian Preeclampsia Family Biobank.
  • Show author(s) 2011. Endoplasmic reticulum stress in decidual tissue from pregnancies complicated by pre-eclampsia and fetal growth restriction.
  • Show author(s) 2010. Medical abortion between 9 and 12 weeks gestation. Experiences from a nursing perspective. .
  • Show author(s) 2010. Classification of pre-eclamptic pregnancies in health registries. An evaluation of criteria selected and pregnancies included in the Medical Birth Registry of Norway.
  • Show author(s) 2010. Biobanking of tissue and blood from pregnancies.
Academic literature review
  • Show author(s) 2020. The emerging role of cd24 in cancer theranostics—a novel target for fluorescence image-guided surgery in ovarian cancer and beyond. Journal of Personalized Medicine. 1-18.
  • Show author(s) 2020. TLR3 expression by maternal and fetal cells at the maternal-fetal interface in normal and preeclamptic pregnancies. Journal of Leukocyte Biology. 1-11.
  • Show author(s) 2018. Epigenome-based cancer risk prediction: Rationale, opportunities and challenges. Nature Reviews Clinical Oncology. 292-309.
  • Show author(s) 2016. No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology. 386-401.
  • Show author(s) 2012. Respiratory health in women: from menarche to menopause. Expert Review of Respiratory Medicine. 187-202.
Article in business/trade/industry journal
  • Show author(s) 2014. Antikoagulasjon ved venøs trombose i svangerskapet. Tidsskrift for Den norske legeforening. 926-926.

More information in national current research information system (CRIStin)